GlassScriptPhysician profile
Timothy Clayton Talbert
NPI 1356338776
$11,840.60
in general payments reported to CMS, 2019-2025
62 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,998 · 2020: $381 · 2021: $1,803 · 2022: $2,354 · 2023: $1,805 · 2024: $1,823 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,304.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.16 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,208.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $863.30 | 2019-2025 | |
| Novo Nordisk INC | $756.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $708.82 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.00 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $427.35 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Antares Pharma, INC. | $394.10 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $379.41 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.13 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $340.54 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $241.77 | 2019-2025 | |
| Abbott Laboratories | $221.38 | 2021-2025 | Freestyle Libre 3, Afinion 2 |
| Teva Pharmaceuticals USA, INC. | $191.76 | 2019-2023 | Austedo |
| Amarin Pharma, INC. | $182.75 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Talbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.